Leerink Partners upgrades Halozyme Therapeutics Inc (HALO) rating to a Market perform

Anna Perez

Halozyme Therapeutics Inc’s recently made public that its PRESIDENT AND CEO Torley Helen unloaded Company’s shares for reported $1.41 million on Nov 12 ’25. In the deal valued at $70.55 per share,20,000 shares were sold. As a result of this transaction, Torley Helen now holds 733,719 shares worth roughly $51.38 million.

Then, Torley Helen sold 20,000 shares, generating $1,382,600 in total proceeds. Upon selling the shares at $69.13, the PRESIDENT AND CEO now owns 733,719 shares.

Before that, Torley Helen sold 20,000 shares. Halozyme Therapeutics Inc shares valued at $1,374,339 were divested by the PRESIDENT AND CEO at a price of $68.72 per share. As a result of the transaction, Torley Helen now holds 733,719 shares, worth roughly $51.38 million.

Leerink Partners upgraded its Halozyme Therapeutics Inc [HALO] rating to a Market perform from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who increased its forecast for the stock in early August from “an Equal-weight” to “an Overweight”. Morgan Stanley revised its rating on May 14, 2025. It rated HALO as “an Equal-weight” which previously was an “an Overweight”.

Price Performance Review of HALO

On Friday, Halozyme Therapeutics Inc [NASDAQ:HALO] saw its stock fall -1.63% to $70.03. Over the last five days, the stock has gained 2.62%. Halozyme Therapeutics Inc shares have risen nearly 17.48% since the year began. Nevertheless, the stocks have risen 46.48% over the past one year. While a 52-week high of $79.50 was reached on 09/23/25, a 52-week low of $42.01 was recorded on 05/14/25.

Levels Of Support And Resistance For HALO Stock

The 24-hour chart illustrates a support level at 69.32, which if violated will result in even more drops to 68.60. On the upside, there is a resistance level at 71.14. A further resistance level may holdings at 72.26.

How much short interest is there in Halozyme Therapeutics Inc?

A steep rise in short interest was recorded in Halozyme Therapeutics Inc stocks on 2025-10-31, growing by 0.51 million shares to a total of 11.31 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 10.8 million shares. There was a rise of 4.49%, which implies that there is a positive sentiment for the stock.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.